The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.
Penumbra wins CE mark for Thunderbolt clot removal tech Read More »
The drug middlemen lobby has had a busy week. It’s the second major lawsuit the PCMA has filed against a state law reforming the PBM industry since Monday.
In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced
From fragile skin to living medicine: Lessons from RDEB Read More »
Durante décadas, colocar un implante dental dependió en gran medida de la pericia manual del cirujano y de su capacidad para interpretar radiografías en dos dimensiones. Hoy, ese mismo procedimiento empieza mucho antes de entrar en el quirófano: en una pantalla, …
Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
New biotech cAMPfield emerges with $180M to reshape IBD treatment Read More »
The takeovers depend on Moderna reaching an agreement with the German government, which risks losing investment from drugmakers over planned healthcare reforms.
Moderna mulls deals to rescue German BioNTech plants from closure: report Read More »
El deseo muy extendido de evitar la cirugía para mejorar arrugas y flacidez sitúa a la medicina estética como primera opción para quienes se preocupan por su apariencia. De hecho, son miles las personas que buscan alternativas menos invasivas y, en este escenario, conocer …
HIFU facial: en qué consiste y cómo actúa para el rejuvenecimiento sin cirugía Read More »
RayThera will bring three preclinical assets into the Biogen fold, all with anti-inflammatory activity. The most mature of these assets is expected to enter Phase 1 development in Q3.
Biogen makes up to $1B immuno play with RayThera takeover Read More »
Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
After being rejected in June 2022, GSK paid Spero Therapeutics $66 million for an exclusive worldwide license to develop and commercialize the drug. It’s the second oral antibiotic GSK has brought to market since the beginning of last year.
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI Read More »
